Drug Profile

Recilisib - Traws Pharma

Alternative Names: Ex-RAD; ON 01210.Na; ON-01210; ON-01210-Na; Recilisib sodium

Latest Information Update: 04 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Onconova Therapeutics
Developer Traws Pharma
Class Radioprotectives; Small molecules; Sulfonamides
Mechanism of Action Apoptosis inhibitors; Protein kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Acute radiation syndrome
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Discontinued Acute radiation syndrome

Most Recent Events

02 Apr 2024 Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
31 Dec 2020 Discontinued - Phase-I for Acute radiation syndrome (In volunteers) in USA (PO)
31 Dec 2020 Discontinued - Phase-I for Acute radiation syndrome (In volunteers) in USA (SC)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com